Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects

What Was Tested

The paper reports a study of Teriparatide and Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.

The recombinant human parathyroid hormone (1-34) (rhPTH[1-34]) teriparatide is the first anabolic agent approved by the US Food and Drug Administration for the treatment of osteoporosis in men and women.

This study was conducted to provide support for marketing authorization of an agent biosimilar to teriparatide in China.

Who Took Part

The study group was 1, subjects.

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized and open-label.

Random assignment meant chance, not the researchers, decided who got Teriparatide and who got the comparison, which limits bias.

Being open-label, the Teriparatide study did not mask who received what.

What Was Measured

PubMed files the paper under topics including Asian People, Bone Density Conservation Agents, Healthy Volunteers, Teriparatide and United States.

Author keywords: recombinant human parathyroid hormone (1–34), safety profile and tolerability.

What This Means in Plain Language

The paper is a randomized and open-label study of Teriparatide and Parathyroid Hormone (PTH 1-84) in 1, subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (Clinical therapeutics), a journal based in United States.

More context: the Teriparatide compound page and the Parathyroid Hormone (PTH 1-84) compound page, all human trials.